MedTrace Logo

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

NCT00641160 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2008-09-26

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for which there are no currently accepted therapies.

Conditions

  • Nonhematologic Malignancies

Interventions

DRUG

vinorelbine tartrate

Dose Level #1 PO for at least 7 days

DRUG

vinorelbine tartrate

Dose Level #2 PO for at least 7 days

DRUG

vinorelbine tartrate

Dose Level #3 PO for at least 7 days

Sponsors & Collaborators

  • Metronome Therapeutics

    lead INDUSTRY

Principal Investigators

  • George Tidmarsh, MD, PhD · Metronome Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641160 on ClinicalTrials.gov